ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting

    Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease

    Annette de Thurah1,2, Ina Trolle Andersen3, Andreas Bugge Tingaard4, Josephine Therkildsen5, Anders Hammerich Riis3, Morten Böttcher5 and Ellen-Margrethe Hauge6,7, 1Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, 2Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 4Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, 5Cardiology, Regional Hospital of Herning, Herning, Denmark, 6Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 7Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
  • Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting

    Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial

    Renaud Felten1, Marie-Alexandra Alyanakian2, Lucienne Chatenoud2, Jean Sibilia1, Frédérique Gandjbakhch3, Cédric Lukas4 and Jacques-Eric Gottenberg1, 1University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, 2Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, 3Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, 4University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France

    Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
  • Abstract Number: 1452 • 2018 ACR/ARHP Annual Meeting

    Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis

    Shinya Kawashiri1, Keita Fujikawa2, Ayako Nishino1, Ayuko Takatani1, Toshimasa Shimizu1, Masataka Umeda1, Shoichi Fukui1, Takashi Igawa1, Tomohiro Koga1, Naoki Iwamoto1, Kunihiro Ichinose1, Mami Tamai1, Hideki Nakamura1, Tomoki Origuchi3 and Atsushi Kawakami1, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: We conducted this retrospective study to determine objective and comprehensive diagnostic criteria for early rheumatoid arthritis (RA) that are based on ultrasound (US) and…
  • Abstract Number: 1470 • 2018 ACR/ARHP Annual Meeting

    Russell Bodies and Serological Status in Rheumatoid Arthritis

    Michael A. McNamara1, Susan M. Goodman2, Laura T. Donlin3, Dana Orange4, Serene Z. Mirza1, Jackie Szymonifka2, Mark P. Figgie5, Vivian P. Bykerk2 and Edward F. DiCarlo6, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 4Rockefeller University, New York, NY, 5Surgery, Hospital for Special Surgery, New York, NY, 6Laboratory Medicine, Hospital for Special Surgery, New York, NY

    Russell Bodies and Serological Status in Rheumatoid Arthritis Background/Purpose: Russell bodies (RBs) are globular aggregates of immunoglobulin produced by plasma cells and identified both within…
  • Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting

    Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis

    Peter M. Maloley1, Bryant R. England2, Harlan Sayles1, Geoffrey M. Thiele1, Michael J. Duryee3, Jeffrey Payne4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, 5Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

     Background/Purpose:  Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
  • Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients

    Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy

    Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
  • Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model

    Yoshikazu Ogawa1, Nobunori Takahashi2, Toshihisa Kojima2 and Naoki Ishiguro2, 1Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, 2Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…
  • Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting

    The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA)  for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Farideh Alasti2, Paul Studenic1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
  • Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting

    Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics

    Damemarie Paul1, Laura McDonald2, Aarti Rao3, Ruthwik Anupindi4 and Keith Knapp5,6, 1HEOR, Bristol Myers Squibb, Lawrence Township, NJ, 2CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, 3Analytics, Mu-Sigma, Bengaluru, India, 4Analytics, Mu-Sigma, Lawrence Township, NJ, 5Arthritis Northwest PLLC., Spokane, WA, 6Discus Analytics LLC., Spokane, WA

    Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…
  • Abstract Number: 1819 • 2017 ACR/ARHP Annual Meeting

    Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity

    Caitrin Coffey1, Cynthia S. Crowson2, Elena Myasoedova3, Eric L. Matteson4 and John M. Davis III5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Evidence supports a therapeutic window of opportunity in early rheumatoid arthritis (RA), during which DMARD therapy most effectively improves clinical outcomes. The 2010 ACR/EULAR…
  • Abstract Number: 2016 • 2017 ACR/ARHP Annual Meeting

    Favourable Changes in Power Doppler Scores in the Feet over 1-Year in an Early Rheumatoid Arthritis Cohort: The Role of Rheumatoid Factor and Anti–Citrullinated Protein Antibody

    Karen A. Beattie1, Hanyan Zou2, George Ioannidis3 and Maggie Larche1, 1Medicine, McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

    Background/Purpose : MTP joints are seldom examined in routine clinical visits. As such, it is important to understand how the standard treatment of patients with…
  • Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons

    Corinne Kowal1, Carey Shive2,3, Elizabeth Zebrowski4,5, Lenche Kostadinova1,6, Brianna Fuller1,6, Elane Reyes2, Kelsey Rife4, Amy Hirsch4, Anita Compan4, Shyam Kottilil7, Yngve Falck-Ytter6,8, Leonard H. Calabrese9, Donald Anthony4,6,10,11 and Maya Mattar6,12, 1Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, 2Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, 3VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, 4Louis Stokes VA Medical Center, Cleveland, OH, 5Department of Medicine, Case Western Reserve University, Cleveland, OH, 6Case Western Reserve University, Cleveland, OH, 7IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, 8Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, 9Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, 10Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, 11VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, 12Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH

    Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
  • Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting

    The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients

    Emma de Moel1, Veerle Derksen1, LA Trouw1, Holger Bang2, R.J. Goekoop3, I Speyer4, TWJ Huizinga1, CF Allaart1, REM Toes1 and Diane van der Woude5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Haga Hospital, The Hague, Netherlands, 4Haaglanden Medical Center, The Hague, Netherlands, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
  • Abstract Number: 72 • 2017 ACR/ARHP Annual Meeting

    The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients

    Onno J. Arntz1, Bartijn C.H. Pieters1, Rogier Thurlings2, Peter M. van der Kraan3, F van den Hoogen2 and Fons A.J. van de Loo3, 1Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, 2Rheumatology, Radboudumc, Nijmegen, Netherlands, 3Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Tumor-necrosis factor (TNF)-α plays a key role in the pathophysiology of rheumatoid arthritis (RA) and membrane bound TNFα is sufficient to induce arthritis in…
  • Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting

    Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients

    Annelies Blanken1, Marian van Beers-Tas1, Marlies Meursinge Reynders1 and Dirkjan van Schaardenburg1,2, 1Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands

    Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology